WALTHAM, Mass., May 14, 2019 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we")
(Nasdaq:SNDX), a clinical stage biopharmaceutical company
developing an innovative pipeline of cancer therapies, today
announced that Briggs W. Morrison,
M.D., Chief Executive Officer of Syndax, will present at the UBS
Global Healthcare Conference on Tuesday, May
21, 2019 at 10:30 a.m. ET at
the Grand Hyatt New York.
A live webcast of the Company's presentation can be accessed
from the Investor section of the Company's website at
www.syndax.com, where a replay of the events will also be available
for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies. The
Company is developing its lead product candidate, entinostat, a
once-weekly, oral, small molecule, class I HDAC inhibitor, in
combination with exemestane and has evaluated it in combination
with several approved PD-1/PD-(L)1 antagonists. The Company's
pipeline also includes SNDX-5613, a selective inhibitor of Menin -
MLL-r binding, and SNDX-6352, a monoclonal antibody that blocks the
colony stimulating factor 1 (CSF-1) receptor. For more information,
please visit www.syndax.com or follow the Company on
Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Tel 212.600.1902
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-to-present-at-the-ubs-global-healthcare-conference-300849336.html
SOURCE Syndax Pharmaceuticals, Inc.